Used in situations involving certain distressing symptoms related to physical discomfort, inflammation, and fever. It is commonly used when short-term symptomatic assistance is needed to address symptoms associated with acute or episodic changes. The medication is generally used for the management of mild to moderate pain and the signs of certain arthritic conditions.

It is relevant in conditions characterized by periods of heightened symptoms, notably assisting with managing primary dysmenorrhea (menstrual cramps) and signs and symptoms of inflammatory disorders such as osteoarthritis and rheumatoid arthritis. This medication helps address symptom clusters that may become intense or disruptive, especially those linked to inflammatory or irritative states.

Quick Fact: Support for Acute and Chronic Discomfort

The medication is applied in addressing symptoms related to both acute discomfort (like strains and sprains) and chronic stiffness (related to arthritis), supporting patients during episodes of heightened discomfort.

Regulatory References

1. FDA-Approved Diclofenac Potassium Indications

Eligibility for Clofast-P

Clofast-P, which contains diclofenac, is officially designated for use in Adults (18 years of age and older). Pediatric use has generally not been established for this medicine.

Populations for Whom Use is Contraindicated

This medicine is strictly contraindicated (must not be used) for individuals with the following conditions, as stated in regulatory documents:

• A known hypersensitivity or allergic reaction (such as asthma or hives) to diclofenac, aspirin, or any other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).
• Established Ischemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Disease, or Congestive Heart Failure (New York Heart Association classification II-IV).
• Use during the perioperative period in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Restricted or Limited Use

Use is subject to caution or is avoided in the following circumstances:

• Pregnancy: Use is generally avoided starting at 30 weeks gestation and later due to the risk of premature closure of the fetal ductus arteriosus. Limited use between 20 and 30 weeks requires careful consideration due to risks of fetal renal dysfunction.
• Advanced Renal Disease: Avoid use unless the benefits are expected to outweigh the risk of worsening kidney function.
• Severe Heart Failure or a recent Myocardial Infarction (MI): Avoid use unless the benefits clearly outweigh the risk of worsening the condition.
• Geriatric patients with certain cardiovascular or renal risk factors.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the active ingredient, Diclofenac Potassium, as described in government regulatory labeling. The information is strictly limited to formal interaction outcomes and restrictions.

Documented Interaction Classifications

Exposure and Clearance Alterations

Co-administration with CYP2C9 inhibitors (e.g., Voriconazole) may result in an increase in Diclofenac Potassium plasma exposure, potentially enhancing toxicity. Conversely, CYP2C9 inducers (e.g., Rifampin) may reduce exposure. Diclofenac Potassium is also documented to reduce the renal clearance of Lithium, which can elevate plasma lithium levels, and inhibit the tubular clearance of Methotrexate.

Cardiovascular and Substance Interactions

This medicine may diminish the antihypertensive effect of ACE Inhibitors and ARBs, and reduce the natriuretic effect of Diuretics. The risk of stomach bleeding is officially documented to increase with the co-ingestion of alcohol. In specific formulations, administration with food is noted to reduce effectiveness and should be avoided.

Modulating Local Chemical Messengers

Clofast-P acts peripherally by directly inhibiting specific Cyclooxygenase (COX) enzymes. This interference with the Arachidonic Acid Pathway halts the production of sensitizing chemicals, which modifies the downstream effects of elevated mediator activity and alters the localized physiological feedback loops.

Central Pathway Regulation and Signal Control

The drug exerts a separate central action by modulating neurotransmitter reuptake in the brain and spinal cord, specifically targeting the Central Descending Inhibitory Pathway. This mechanism influences signaling activity, resulting in an increase in the degree of central inhibitory signaling within the body's sensory processing pathways.

Thermoregulatory Reset and Mechanistic Synergy

Clofast-P's components operate in a complementary, dual-action synergy: one targets peripheral chemical production, and the other modulates central signal processing. A specific central action also adjusts the body's hypothalamic set point to manage temperature. This mechanistic cascade results in alterations to physiological parameters by engaging systems that influence the processing of sensory input and the management of core body temperature.

How Clofast-P is Used: Administration Guidelines

Clofast-P (Diclofenac Potassium) is used according to specific instructions detailing the administration route, dosage limits, and intake conditions.

Administration Scope

Instructions for Intake

The preparation requirements differ based on the specific formulation being used:

• Clofast-P Tablets: The immediate-release tablets are to be swallowed whole with liquid and may be taken with or after food to ease discomfort.
• Clofast-P Powder for Oral Solution: The powder must be mixed with a small amount of water, typically 1 to 2 ounces, and consumed immediately. For acute relief, this form is often directed to be taken on an empty stomach.

Dosing Rules for Specific Populations

• Older Adults: While no mandatory dose reduction is specified, the lowest effective dose should be used, reflecting general clinical guidance for NSAID use in this group.

Following these administration rules is essential for using the medicine as intended. Different formulations, such as other salt forms or extended-release products, are not interchangeable on a milligram-per-milligram basis.

Research evidence / Overview of Studies for Clofast-P

The clinical evaluation of Clofast-P, which contains Diclofenac Potassium, is documented through Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. This research explores how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, and the findings help contextualize how patients reported their experience during the study periods.

Evidence for Studies Examining Acute Pain

The research base for studies examining acute pain, such as that experienced after dental procedures or surgical events, is primarily built on Randomized Controlled Trials (RCTs) involving adult patient cohorts. Researchers examined endpoints such as the change in pain intensity at fixed time points and the time elapsed until patients used rescue pain medication. Findings described patterns related to the time to onset of measurable symptomatic assessment changes. However, follow-up durations were limited, often restricted to the first 4 to 8 hours after a single dose, providing restricted information regarding consistency for recurring acute episodes.

Evidence for Studies in Menstrual Pain (Primary Dysmenorrhea)

The evidence for primary dysmenorrhea involves RCTs and studies utilizing crossover designs. The study cohorts included young women experiencing phases of heightened symptom activity, and researchers tracked the severity of menstrual pain over defined short time periods. This evidence contributes to understanding symptom patterns, particularly concerning episodic changes in discomfort. What remains uncertain is the performance or consistency of the medicine when used across multiple, consecutive menstrual cycles, as the existing research primarily provides context about the immediate, short-duration response.

Limitations and Research Uncertainty

The data available for the immediate-release Potassium salt form for chronic conditions like Osteoarthritis and Rheumatoid Arthritis remains insufficient compared to the extensive data available for other Diclofenac formulations. Evidence quality varies across studies, and the existing evidence is often characterized by scientific reviews as having an assessment of Moderate. Follow-up durations were limited, restricting insight into the impact of recurring or long-term use. Subgroup findings are uncertain, as most trials excluded patients with significant co-existing conditions, meaning the results apply only to the populations studied. Research does not determine whether an individual will respond similarly, and findings describe group patterns, not personal outcomes.

Key Studies & References Diclofenac Potassium Tablets U.S. FDA-Approved Drug Labeling and Indications

Common questions about Clofast-P (FAQ)

Q: What is Clofast-P used for?

A: Clofast-P (Diclofenac Potassium) is an oral medication that belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It is typically considered for use in the temporary relief of mild to moderate pain, and for reducing fever. Its approved uses often include short-term treatment of conditions such as acute back pain, headache, dental pain, and symptoms associated with colds or influenza.

Q: How does Clofast-P function to address pain?

A: Clofast-P is understood to work by interacting with specific enzymes in the body, primarily cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2). By inhibiting these enzymes, the drug is observed to interfere with the production of prostaglandins, which are compounds in the body involved in signaling pain and inflammation. This action may contribute to reduced pain and inflammatory response.

Q: Can Clofast-P be taken with other pain relievers?

A: Before combining Clofast-P with any other pain relievers, especially other NSAIDs, it is important to discuss the potential risks with a healthcare provider. Combining certain pain medications may increase the likelihood of side effects, such as stomach upset or gastrointestinal bleeding. A healthcare professional can provide guidance based on your specific health profile.

Q: Are there important safety considerations for Clofast-P?

A: Like all medications, Clofast-P carries potential risks. The use of NSAIDs, including Clofast-P, has been associated with an increased chance of certain cardiovascular events, such as heart attack or stroke, particularly with long-term use or high doses. There is also a risk of serious gastrointestinal issues, including bleeding or ulcers in the stomach or intestines. It is important to review all known risks with a physician.

Q: How long can Clofast-P be used for pain or fever?

A: For over-the-counter use in the United States, the medication is generally intended for short-term use. For pain, it is often recommended not to exceed five days of use, and for fever, not more than three days, unless specifically directed and monitored by a healthcare professional. Chronic use of NSAIDs should be discussed with a doctor due to potential risks.

Clofast-P tablets should be stored at room temperature, generally below 30 C (86 F), unless otherwise specified on the packaging. It is essential to protect the medicine from moisture and light. Always keep the tablets in their original, tightly closed container or packaging to maintain their stability.

Storage and Security

• Store Clofast-P out of the sight and reach of children and pets to prevent accidental ingestion, as this poses a significant poisoning risk.
• Do not store the medicine in damp areas, such as bathrooms, as excessive heat and humidity can compromise its effectiveness.

Proper Disposal

• Do not dispose of Clofast-P by flushing it down a toilet or pouring it into a drain, as this can pose risks to the environment.
• The best method for disposal is to use a community drug take-back program or return the unused or expired medicine to a local pharmacy for safe, authorized destruction.
• If no take-back program is available, mix the medicine with an undesirable substance (like used coffee grounds or cat litter) to make it unappealing, place the mixture in a sealed plastic bag, and discard it in the household trash. Be sure to scratch out all personal information on the prescription label.